Ascletis Pharma Inc.
Ascletis Pharma Inc. is a Cayman Islands exempted company incorporated on 25 February 2014, with company registration number 285549 and its registered office at 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. Trading as 歌禮製藥有限公司, the company has been listed on the Main Board of the Hong Kong Stock Exchange since August 2018 under stock code 1672 and remained listed as of 2026, based on its 2026 annual general meeting notice and subsequent share-repurchase filings. Ascletis Pharma Inc. operates as an investment holding company; its pharmaceutical research, development, manufacturing and commercialisation activities are carried out through operating subsidiaries based in Hangzhou, Zhejiang Province, in mainland China. Historically, the group discovered and commercialised danoprevir (marketed in China as Ganovo) for chronic hepatitis C and developed ASC22, a candidate for a functional cure of chronic hepatitis B and HIV, alongside a non-alcoholic steatohepatitis (NASH) programme conducted through its subsidiary Gannex Pharma Co., Ltd. Since September 2024, Ascletis Pharma Inc. has redirected the majority of its research and development toward metabolic and weight-management therapies. Its lead metabolic candidate, ASC30, is an oral small-molecule GLP-1 receptor agonist for which the company initiated a global Phase III programme intended to enrol approximately 4,600 participants with obesity or overweight across the United States, Europe and Canada, with a planned U.S. New Drug Application submission targeted for late 2028. Additional pipeline candidates include the amylin receptor agonists ASC36 and ASC39 and fixed-dose GLP-1/amylin combinations. No stock-exchange financial results for a specific reporting year are summarised here; readers should refer to Ascletis Pharma Inc.’s latest annual report and interim results filed with HKEXnews for reported revenue and operating figures. This description does not address the company’s directors, shareholders or corporate group, which are covered in separate sections of this profile.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Ascletis Pharma Inc.
Ascletis Pharma Inc. is a Hong Kong Stock Exchange-listed company (stock code 1672), and as such its shareholder disclosure follows HKEX Listing Rules rather than a general public shareholder register. Under those rules, the company must disclose to HKEXnews any interest held by a director, chief executive or substantial shareholder in 5% or more of its issued shares, together with changes in a controlling shareholder’s interest, rather than publishing a complete register of all shareholders. Ascletis Pharma Inc.’s own filings identify Dr. Jinzi Jason Wu, the company’s founder, chairman and chief executive officer, together with his spouse Mrs. Judy Hejingdao Wu, as controlling shareholders of the company for the purposes of the Listing Rules. Beyond this founder and family interest, the sources reviewed for this profile did not provide a complete, dated list of every substantial shareholder and exact holding.
Ultimate beneficial ownership
Dr. Jinzi Jason Wu is publicly identified in Ascletis Pharma Inc.’s corporate disclosures as a controlling shareholder and the company’s founder. Several financial-data providers reported his direct and family shareholding at just above 50% of the company as of 2025, following a partial share disposal reported during that year, but this profile does not state an exact calculated percentage as current ultimate beneficial ownership, because no primary HKEXnews disclosure-of-interest filing stating an exact, dated shareholding percentage was independently reviewed while preparing this profile. Readers who require the precise current percentage should consult Ascletis Pharma Inc.’s latest disclosure-of-interest filings and annual report on HKEXnews.
Data availability
Shareholder and beneficial-ownership information for Ascletis Pharma Inc. is classified as major shareholders only: as an HKEX-listed company its founder and controlling shareholders are named in regulatory filings, but a complete shareholder register comparable to a private-company register is not published. This should not be read as evidence that no other shareholders exist beyond those named here.
Sources
- HKEXnews, Ascletis Pharma Inc. company announcements, stock code 1672, https://www.hkexnews.hk, retrieved 18 September 2026.
- Ascletis Pharma Inc. 2018 HKEX listing prospectus and related HKEXnews filings referencing the controlling shareholder status of Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu.
Officers
Directors and officers of Ascletis Pharma Inc.
Ascletis Pharma Inc.’s board, as disclosed in its HKEX filings, comprises two executive directors and three independent non-executive directors. The executive directors are Dr. Jinzi Jason Wu, who is the company’s founder, chairman of the board and chief executive officer, and Mrs. Judy Hejingdao Wu. The independent non-executive directors are Mr. Jiong Gu, who chairs the Audit Committee, Dr. Yizhen Wei and Ms. Lin Hua; all three were appointed as independent non-executive directors on 27 April 2018, around the time of the company’s HKEX listing. No resignation of a current board member was identified in the sources reviewed for this profile.
Data availability
Director information for Ascletis Pharma Inc. is disclosed under HKEX Listing Rules in its listing documents, circulars and annual reports, which is treated as full for current board composition. Nationality is not stated for the directors named above in the sources reviewed for this profile and is therefore reported here as not disclosed; it should not be inferred from any director’s name or reported place of residence.
Sources
- HKEXnews, Ascletis Pharma Inc. company announcements and circulars, stock code 1672, https://www.hkexnews.hk, retrieved 18 September 2026.
Group Structure
Group structure of Ascletis Pharma Inc.
Ascletis Pharma Inc. is the Cayman Islands-incorporated parent of a group whose pharmaceutical research, development, manufacturing and commercialisation activities are carried out through operating subsidiaries based in Hangzhou, Zhejiang Province, mainland China. No corporate parent above Ascletis Pharma Inc. was identified; the company is itself listed on the Hong Kong Stock Exchange under stock code 1672. Company announcements and press materials identify Gannex Pharma Co., Ltd. as a wholly-owned subsidiary dedicated to the research and development of therapies for non-alcoholic steatohepatitis (NASH) and related metabolic-liver conditions. The sources reviewed for this profile did not provide a complete list of every intermediate holding company or mainland China operating subsidiary between the Cayman Islands parent and its operating businesses, nor the registration numbers or exact ownership percentages of each entity beyond the wholly-owned characterisation reported for Gannex Pharma Co., Ltd.
Data availability
Corporate-linkage information for Ascletis Pharma Inc. is classified as partial: its status as an independent, HKEX-listed ultimate parent is confirmed, and at least one wholly-owned subsidiary is named in company disclosures, but a complete subsidiary list with jurisdictions, registration numbers and ownership percentages for every group entity was not located in the sources reviewed. This should not be read as evidence that no further subsidiaries exist.
Sources
- Ascletis Pharma Inc. company announcements and press materials referencing Gannex Pharma Co., Ltd. as a wholly-owned NASH-focused subsidiary, retrieved 18 September 2026.
- HKEXnews, Ascletis Pharma Inc. company announcements, stock code 1672, https://www.hkexnews.hk, retrieved 18 September 2026.
Registry feed — rows exactly as filed with Cayman Islands General Registry, including entries the profile above does not cover.
JJW12 Limited
British Virgin Islands
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What is Ascletis Pharma Inc.?
Ascletis Pharma Inc. is a Cayman Islands-incorporated biopharmaceutical company (trading as 歌禮製藥有限公司) listed on the Hong Kong Stock Exchange under stock code 1672, engaged in the research, development and commercialisation of pharmaceutical products primarily through operating subsidiaries in mainland China.
Where is Ascletis Pharma Inc. incorporated?
Ascletis Pharma Inc. is incorporated in the Cayman Islands as an exempted company with limited liability, with its registered office at 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.
What is Ascletis Pharma Inc.'s company registration number?
Ascletis Pharma Inc.'s on-file company registration number is 285549, assigned by the Cayman Islands General Registry.
Was Ascletis Pharma Inc. incorporated on 1 January 2018?
No. The 1 January 2018 date on file for this profile is a placeholder rather than a verified incorporation date. According to Ascletis Pharma Inc.'s Hong Kong Stock Exchange listing prospectus and related HKEXnews filings, the company was incorporated in the Cayman Islands on 25 February 2014. The 2018 date likely reflects the year of the company's HKEX listing rather than its incorporation.
Is Ascletis Pharma Inc. publicly listed?
Yes. Ascletis Pharma Inc. has been listed on the Main Board of the Hong Kong Stock Exchange since August 2018 under stock code 1672, and remained listed as of 2026 based on its annual general meeting notices and share-repurchase filings.
What is Ascletis Pharma Inc.'s stock ticker?
Ascletis Pharma Inc. trades on the Hong Kong Stock Exchange under stock code 1672.
What does Ascletis Pharma Inc. do?
Ascletis Pharma Inc. is an investment holding company whose subsidiaries research, develop, manufacture and commercialise pharmaceutical products, historically focused on viral diseases and NASH and, since September 2024, principally on metabolic and weight-management therapies.
What products has Ascletis Pharma Inc. developed?
Ascletis Pharma Inc.'s group has developed danoprevir (marketed in China as Ganovo) for chronic hepatitis C and ASC22 for chronic hepatitis B and HIV, and through its NASH-focused subsidiary Gannex Pharma Co., Ltd. developed candidates targeting FASN, THR-beta and FXR for non-alcoholic steatohepatitis.
What is Ascletis Pharma Inc.'s current lead pipeline programme?
As of its most recent public disclosures, Ascletis Pharma Inc.'s lead programme is ASC30, an oral small-molecule GLP-1 receptor agonist for obesity, for which the company has initiated a global Phase III trial programme.
Who founded Ascletis Pharma Inc.?
Ascletis Pharma Inc. was founded by Dr. Jinzi Jason Wu, who serves as the company's chairman and chief executive officer.
Who are the directors of Ascletis Pharma Inc.?
Ascletis Pharma Inc.'s board comprises executive directors Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, and independent non-executive directors Mr. Jiong Gu, Dr. Yizhen Wei and Ms. Lin Hua.
Who owns or controls Ascletis Pharma Inc.?
Ascletis Pharma Inc.'s regulatory disclosures identify Dr. Jinzi Jason Wu, together with his spouse Mrs. Judy Hejingdao Wu, as controlling shareholders under HKEX Listing Rules; an exact, independently verified current shareholding percentage was not confirmed from a primary filing for this profile.
Does Ascletis Pharma Inc. have subsidiaries?
Yes. Ascletis Pharma Inc. conducts its operations through subsidiaries based in mainland China, including Gannex Pharma Co., Ltd., a wholly-owned subsidiary focused on non-alcoholic steatohepatitis (NASH) drug development.
Does Ascletis Pharma Inc. still develop hepatitis C treatments?
Ascletis Pharma Inc.'s hepatitis C candidate danoprevir (Ganovo) was historically part of its portfolio; since September 2024 the company has redirected the majority of its research and development toward metabolic and obesity-focused programmes such as ASC30.
Where is Ascletis Pharma Inc.'s registered office?
Ascletis Pharma Inc.'s registered office is at 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.